PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30674531-6	2019	Oral administration of a novel small molecule galectin-3 inhibitor GB1107 reduced human and mouse lung adenocarcinoma growth and blocked metastasis in the syngeneic model.	GB1107	67-73	galectin 3	Homo sapiens	46-56	
34373714-10	2021	The addition of the Gal-3 inhibitor GB1107 significantly increased glucose utilization and reduced insulin resistance in PA-treated cells.	GB1107	36-42	galectin 3	Homo sapiens	20-25	
35023445-11	2022	In vitro, co-incubation with a Gal-3 inhibitor (GB1107, 10 microM) led to a significant reduction in both interleukin-1beta and tumour necrosis factor-alpha secretion from FLS monocultures (both p < 0.05) and decreased monocyte-derived osteoclastogenesis compared with controls (both p < 0.05).	GB1107	48-54	galectin 3	Homo sapiens	31-36	
34035807-3	2021	In the present study, we aimed to investigate the therapeutic potential of novel galectin-3 inhibitors by treating thyroid cancer cells with different concentrations of GB1107 or TD139.	GB1107	169-175	galectin 3	Homo sapiens	81-91